
1:35PM



NO. RECEIVED

| Please type a plus sign (+) Inside this box | - |
|---|---|
| bleage tabe e bins agu (,) mans a | |

| | # 1/ I. D. SNUV 2 4 2003 |
|------|--|
| - | Complete if Known TECH CENTER 1600/290 |
| | 09/930,283 |
| | August 16, 2001 |
| or o | Kasid et al. |
| | 1625 |

| | | Complete if Known 11 Oct 1211 1000/2 |
|---|------------------------|--------------------------------------|
| Substitute for form 1449A/B/PTO | Application Number | 09/930,283 |
| Substitute for four 14494577 | | August 16, 2001 |
| INFORMATION DISCLOSURE | First Named Inventor | Kasid et al. |
| STATEMENT BY APPLICANT | Group Art Unit | 1635 |
| | Examiner Name | Terrea C. Gibbs |
| (Use as many sheets as necessary) Sheet 1 of 1 | Attorney Docket Number | 219603 |
| Sheet 1 Of | | |

| | | U.S. Patent Do | cument | Name of Patentee or Applicant | Date of | Filing Date If Appropriate |
|---------------------|------|----------------|--------------|-------------------------------|----------------|-------------------------------|
| Examiner | Doc. | Application or | Kind Code | | Publication | |
| Initials | No. | Patent Number | | Debs et al. | June 24, 1997 | |
| Y | AA | 5,641,662 | | Hostetler et al. | Dec. 9, 1997 | |
| `\ | AB | 5,696,277 | | | Oct. 27, 1998 | |
| | AC | 5,827,703 | | Debs et al. | Sep. 19, 2000 | |
| \dashv | AD | 6,120,798 | | Allen et al. | June 19, 2001 | |
| - 1812 - | AE | 6,248,351 | B1 | Xing et al. | Julie 15, 2001 | |
| - u | 1 | | | | | |
| | ┼── | | 1 | | | |
| - | ├── | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | Trans | lation | | |
|--------------------------|-------------|-------------------------|---------------------------------|--------------|-------------------------------|---------------------|-----|----------|
| | | Foreign Patent Document | | | | | V | |
| xaminer | Doc. No. | Office | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Yes | No |
| Initials | NO. | | , 4.0 | | · | | | —- |
| | | | | + | | Ì <u> </u> | | <u> </u> |
| | L | L.— | | | | | l _ | \ |
| | | l. i | | | | · | | |
| | | | | <u> </u> | | | | ${f t}$ |
| | | 1 | | | | | | ₩ |

| | _ | OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Include name of the author (in CAPITAL LETTERS), date page(s), volume-issue number (s), publisher, | Trans | lation |
|--------------------|-------------|--|-------|--------------|
| miner Initials | Doc. No. | (book, magazine, Journal, senal, symposium, datalog, etc.), date; page(-), date; | Yes | No |
| LSO | AF | GOKHALE et al., "Enhanced inhibition of Raf-1 kinase by liposomal antisense rai oligodeoxyribonucleotide in human squamous carcinoma cells," American Asso. Cancer oligodeoxyribonucleotide in human squamous carcinoma cells," American Asso. Cancer | | |
| | AG | GOKHALE et al., "Antisense raf oligodeoxyribonucleotide is protected by apposition and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and inhibits Raf-1 protein expression | | - |
| | АН | GOKHALE et al., "Antisense raf Oligodeoxynbonucieotide is a Radiosetisiazor," | | ├ |
| | ΑI | LITIZINGER et al., *Fate of cationic liposomes and their complex with oligonistics and their complex with oligonistics. | | ├ |
| | LA | MAHER et al., "Specific Hybridization Arrest of Dinydrotolate Reductase Invited in Vision Using Anti-sense RNA or Anti-sense Oligonucleotides," Archives of Biochemistry and Displaying 253, 214-220 (1987) | | |
|) LY | AK | SOLDAATENKOV et al., "Inhibition of Raf-1 Protein Kinase by Antisense Phosphorothioate Oligodeoxyribonucleotide Is Associated with Sensitization of Human Laryngeal Squamous Carcinoma Cells to Gamma Radiation," Cancer J. Sci. Am., 3, 13-20 (1997) | - | |

| Examiner Signature | · Pure DO | Date Considered | 2/16/04 |
|--------------------|-----------|-----------------|---------|
| | | | • |

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).